Core Insights - The domestic medical beauty market in China is becoming increasingly competitive, with significant price reductions and patent disputes among leading companies [1][3][6] - Major players are expanding overseas as domestic profit margins shrink, indicating a strategic shift towards international markets [1][11] Market Competition - New Oxygen launched a low-priced "Miracle Youth Needle" at 2999 yuan, significantly undercutting competitors and causing dissatisfaction among upstream material suppliers [3][6] - Huaxi Biological and Juzi Biological are engaged in a fierce dispute over collagen product patents, highlighting the intense competition in the market [3][4] - The competition is characterized by a shift from regulatory competition to market-driven competition, with a growing number of brands entering the space [6][7] Financial Performance - Major companies like Aimeike and Huaxi Biological reported significant declines in revenue and net profit, with Aimeike's revenue and net profit down 21.59% and 29.57% respectively in the first half of the year [7][10] - Huaxi Biological's revenue and net profit also fell by 19.57% and 35.38% respectively, marking a continuous decline over two years [7][10] International Expansion - Chinese medical beauty companies are increasingly looking to international markets, with firms like Aimeike and Huaxi Biological investing in overseas partnerships [1][11] - The strategy involves acquiring or investing in foreign companies to introduce Chinese products to international markets, rather than relying on traditional business development methods [11][12] Emerging Markets - There is a growing opportunity in emerging markets such as Southeast Asia and Latin America, where demand for cost-effective and multifunctional products is rising [12][13] - Companies are focusing on building technological barriers and moving away from the "low-price" label by investing in advanced materials and techniques [13]

Core Insights - The Chinese medical aesthetics market is becoming increasingly competitive, with significant price reductions and patent disputes among leading companies [1][2][3] - Major players are expanding internationally as domestic competition intensifies, with companies like Four Rings Pharmaceutical investing in overseas markets [1][9] - The industry is transitioning from a focus on product registration to market-driven competition, leading to a "price war" and a shift towards a more comprehensive competition model involving product, service, and technology [6][10] Market Dynamics - The medical aesthetics industry in China has evolved from a niche market to a significant sector, but the penetration rate of medical aesthetics products remains low compared to mature markets like Europe and the U.S. [1][6] - New Oxygen's introduction of the "Miracle Youth Needle 3.0" at a price point below 3000 yuan marks a significant price drop in the domestic market [1][2] - The competition among major products such as water light needles, youth needles, and recombinant collagen is intensifying, with numerous new products entering the market [4][6] Financial Performance - Leading companies are experiencing significant revenue declines, with Aimeike reporting a 21.59% drop in revenue and a 29.57% decrease in net profit in the first half of the year [7][8] - Huaxi Biological has also seen a continuous decline in annual performance, with a 19.57% drop in revenue and a 35.38% decrease in net profit in the first half of the year [7][8] International Expansion - Chinese medical aesthetics companies are increasingly looking to international markets for growth, with several firms, including Aimeike and Huaxi Biological, investing in overseas companies [9][10] - The global medical aesthetics market is still in a growth phase, but companies face challenges such as regulatory differences, cultural adaptation, and established local competition [10][12] - Emerging markets in Southeast Asia, the Middle East, and Latin America present opportunities for Chinese companies to expand, as these regions show rapid growth in medical aesthetics consumption [12][13]

Core Viewpoint - The company Aimeike reported a decline in revenue and net profit for the first half of the year, attributed primarily to a significant acquisition of the Korean company REGEN, which is expected to impact short-term performance but aims for long-term growth in international markets [1][4][9]. Financial Performance - In the first half of the year, Aimeike achieved revenue of 1.299 billion yuan and a net profit of 791 million yuan, representing year-on-year declines of 21.59% and nearly 30% respectively [1]. - The acquisition of REGEN for approximately 1.386 billion yuan has led to a substantial cash outflow of 9.861 billion yuan in investment activities, nearly doubling year-on-year [4]. Product Performance - Despite the overall decline, the company’s high-margin products, such as the "Haitai" and "Ruhbai Tianzi," continue to support its performance, with gross margins for solution and gel injection products remaining high at 93.15% and 97.75% respectively [4][5]. - The "Haitai" series remains a leading product in the neck wrinkle repair market, maintaining a strong market presence despite competition [5]. Market Strategy - Aimeike is focusing on international expansion to avoid domestic market saturation and profit erosion, as indicated by its acquisition of REGEN [3][9]. - The company has established a robust B2B network with over 7,000 beauty institutions, enhancing its market penetration and customer loyalty [6][7]. Future Outlook - Aimeike's product pipeline is promising, with three major products currently in the review stage for market approval, including a high-end botulinum toxin product expected to capture a significant share of the domestic market [8]. - The domestic botulinum toxin market is projected to grow at a compound annual growth rate of over 15% from 2025 to 2030, indicating strong future demand [8].

Core Insights - The medical beauty industry is undergoing transformation driven by technological advancements and evolving aesthetic perceptions, with non-surgical procedures becoming increasingly popular, particularly in anti-aging treatments [1] - Injection-based aesthetic procedures are gaining traction due to their effectiveness, short recovery times, and high repeat purchase rates, positioning the injection market as a new growth area within the medical beauty sector [1] Injection Aesthetic Concepts and Classification - Injection aesthetic procedures are minimally invasive treatments primarily categorized into hyaluronic acid, botulinum toxin, collagen, regenerative injectables, lipolytic injections, and thread lifting [2] - The market is dominated by hyaluronic acid and botulinum toxin, with botulinum toxin leading globally with 8.878 million treatments in 2023, followed by hyaluronic acid with 5.565 million treatments [2] Market Heat Analysis - The synthetic regeneration field is becoming an investment hotspot, with new materials and combinations expanding market boundaries [5] - By November 2024, 15 injectable products have been approved, primarily hyaluronic acid, with several others including polylactic acid and botulinum toxin [5] Hyaluronic Acid Development Status and Trends - Hyaluronic acid maintains its leading position, with a growth rate of 29.1% from 2022 to 2023, driven by diverse applications and combination treatments [11] - The industry faces challenges such as product homogenization and safety concerns, but innovation and differentiation present opportunities for growth [14][15] Botulinum Toxin Development Status and Trends - The botulinum toxin market is evolving towards a coexistence of natural and recombinant products, with recombinant botulinum toxin expected to penetrate the market due to its safety and customization potential [17] Regenerative Materials Development Status and Trends - Regenerative injectable products, particularly polylactic acid (PLA) and polycaprolactone (PCL), are gaining attention, with hydroxyapatite emerging as a potential market player [23] Collagen Development Status and Trends - The application of collagen in medical aesthetics is expanding, with various types being explored for their unique benefits, particularly types I and III for skin support and hydration [31] User Preferences and Trends - Users increasingly prioritize skin quality and overall facial harmony, with a shift towards personalized beauty standards [39] - The demand for skin improvement remains strong, with private care and hair transplant services emerging as new market opportunities [42] User Decision-Making and Experience - Safety and effectiveness are the primary concerns for users, with a growing emphasis on the qualifications of medical personnel and the quality of procedures over cost [45][60] - Users exhibit a cautious approach to decision-making, with a significant portion requiring thorough research before engaging in aesthetic procedures [47] Market Trends and Future Outlook - The injection aesthetic market is transitioning from simple filling procedures to a focus on long-lasting, precise, and personalized treatments, driven by technological advancements and consumer expectations [68] - Chinese companies are increasingly looking to international markets for growth, with a focus on regulatory compliance and brand recognition to overcome market entry barriers [71]

Group 1 - The core viewpoint of the articles highlights the rapid rise of recombinant collagen in the medical beauty and skincare industry, challenging the dominance of hyaluronic acid [1][2][16] - Jinjian Biological's stock price has surged over 100% since the beginning of the year, reaching a historical high of 442.00 yuan per share, with a listing price of 49 yuan per share in 2023 [1] - The founder of Jinjian Biological, Yang Xia, has seen a significant increase in wealth, ranking 2295th on the Hurun Global Rich List with a net worth of approximately 11.5 billion yuan, up 455 places year-on-year [1] Group 2 - The wealth of founders in the hyaluronic acid sector, such as Zhao Yan of Huaxi Biological and Jian Jun of Aimeike, has declined, indicating a shift in the industry landscape [2] - Huaxi Biological reported a revenue of 5.371 billion yuan in 2024, a year-on-year decrease of 11.61%, and a net profit decline of 70.59% [19] - Aimeike's revenue for 2024 was 3.026 billion yuan, with a slight growth of 5.45%, but faced a decline in net profit [19] Group 3 - Jinjian Biological's revenue for 2024 reached 1.443 billion yuan, a year-on-year increase of 84.92%, with a net profit of 732 million yuan, up 144.27% [6] - The company achieved a gross margin of 95.03% in its medical device segment, surpassing the gross margin of Kweichow Moutai [7] - Jinjian Biological's focus on medical devices and functional skincare products has positioned it as a strong competitor in the market [6][14] Group 4 - The competitive landscape is shifting, with Jinjian Biological and Juzhi Biological both expanding into medical beauty injections, potentially leading to direct competition [13][17] - Jinjian Biological has received approval for its injectable recombinant collagen gel, indicating ongoing product development and market expansion [14] - The industry is witnessing a trend towards international expansion, with companies like Jinjian Biological and Huaxi Biological exploring overseas markets [24][25] Group 5 - The financial performance of Chuangjian Medical has declined, with a revenue of 288.2 million yuan in 2024, a growth of only 1.82%, and a net profit drop of 50.84% [6][15] - Chuangjian Medical is attempting to pivot towards terminal products, including medical devices and cosmetics, but lacks strong competitive advantages [14][15] - The overall market for recombinant collagen is still in its early stages of international expansion, with companies planning to enhance their global presence [25]

点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 事件： 公司发布2025年一季报，1Q2025营业收入为6.6亿元，同比下滑17.9%，归母净利润为4.4亿元，同比下滑 15.9%。 点评： 高基数+产品结构分化，一季度业绩有所下滑 我们认为，公司一季度收入同比下滑主要原因系：第一，去年同期基数较高；第二，产品销售结构性分 化，溶液类产品整体出货价格走低。 产品结构性分化，一季度毛利率略有下滑 1Q2025，公司毛利率为93.9%，同比-0.7pcts；归母净利率为66.9%，同比+1.6pcts。我们认为，公司一季 度毛利率同比微降也是受产品出货结构的影响。 1Q2025公司期间费用率同比+4.1pcts至21.9%。分项目看，销售/管理/研发/财务费用率分别为 9.9% ...